| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/15/2004 | US20040137068 A sterile formulation of a biocompatible chelating agent, a permeability promoter, Advanced Glycation Endproducts (AGE) selected from breakers, formation inhibitors, and glycation inhibitors and a carrier; vision defects; inserts |
| 07/15/2004 | US20040137066 treating vascular disease by diagnosing the pathology and then coating the implant with the appropriate therapeutic agent to treat it; coating contaings a mixture of rapamycin and another therapeutic agent |
| 07/15/2004 | US20040137051 Wound healing compositions and methods of use |
| 07/15/2004 | US20040137034 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 07/15/2004 | US20040137017 amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment of the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment, where in Ser-63 and Arg-192 are replaced with another amino acid |
| 07/15/2004 | US20040137009 DNA encoding a derivative of a human interferon- alpha selected from DNA encoding a protein in which one or more amino acid residues of the protein encoded by the above DNA have been replaced, deleted, and/or added |
| 07/15/2004 | US20040137008 Non-splicing variants of gp350/220 |
| 07/15/2004 | US20040137006 an anti-allergic agent, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells |
| 07/15/2004 | US20040137005 Chlamydia protein, sequence and uses thereof |
| 07/15/2004 | US20040137001 Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse |
| 07/15/2004 | US20040136997 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 07/15/2004 | US20040136995 antibody, or fragment thereof, that specifically binds an ACT-4-h-1 receptor; has different binding specificity than a monoclonal antibody generated by hybridoma HBL106 |
| 07/15/2004 | US20040136993 inducing an immunogenic response against alpha-SN |
| 07/15/2004 | US20040136992 modulating inflammatory and immunoregulatory responses associated with cardiovascular disease with soluble receptor, fusion proteins, and/or antibodies of IL-17, IL-18 antagonist, 4-1BB, CD30 and OX40 |
| 07/15/2004 | US20040136987 Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
| 07/15/2004 | US20040136984 Mammalian galanin receptors |
| 07/15/2004 | US20040136983 as anti-tumor agent or treating excessive vascular permeability; agonist for treating trauma to vascular network |
| 07/15/2004 | US20040136979 block, retard or reduce connective tissues regeneration; molecules released by catheters, surgical instruments or stents for angioplasty to prevent restenosis; atherosclerosis |
| 07/15/2004 | US20040136978 relates to the surprising finding that overexpression of ABIN prevents TNF-induced lethal hepatitis in mice |
| 07/15/2004 | US20040136976 screening for agents which decrease extracellular matrix degradation; |
| 07/15/2004 | US20040136975 Mitogen activated protein kinase inhibitors |
| 07/15/2004 | US20040136970 negatively charged carrier, such as hyaluronic acid, are administered to a synovial joint, the stimulatory effects of the FGF18 are enhanced |
| 07/15/2004 | US20040136969 cellular composition consisting of greater than 20% adult bone marrow derived cells, depleted of hematopoietic cells and matured leucocytes; having phenotype of CD45-, Lin- and Sca+ |
| 07/15/2004 | US20040136966 implantation of hematopoietic stem cells into the myocardium surrounding an infarct following a myocardial infarction, migrate into the damaged area, where they differentiate into myocytes, endothelial cells and smooth muscle cells |
| 07/15/2004 | US20040136959 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il -13 receptor alpha chain |
| 07/15/2004 | US20040136957 administering a therapeutically relevant dose of IFN (interferon) type-I or a functional part, derivative and/or analogue thereof |
| 07/15/2004 | US20040136956 Asialo-interferons and the treatment of liver cancer |
| 07/15/2004 | US20040136955 Modified asialo-interferons and uses thereof |
| 07/15/2004 | US20040136954 Methods and compositions for modulating T helper (Th) cell development and function |
| 07/15/2004 | US20040136953 diagnosing aggressive form of respiratory condition by a different T helper cell response when samples are incubated with antigen characteristic of condition; treatment with interferon gamma |
| 07/15/2004 | US20040136952 with water-soluble polymers, e.g., poly(ethylene glycol); coupling with amino-terminal amino acid located remotely from one or more receptor-binding domains of said cytokine, chemokine, growth factor or polypeptide hormone, or antagonist thereof |
| 07/15/2004 | US20040136951 Death domain containing receptor 5 |
| 07/15/2004 | US20040136950 enhancing apoptosis induced by a TNF-family ligand, which involves administering to a cell that expresses the DR4 polypeptide an effective amount of an agonist capable of increasing DR4 mediated signaling |
| 07/15/2004 | US20040136949 Combination therapy using anti-angiogenic agents and tnf alpha |
| 07/15/2004 | US20040136947 Polymeric prodrugs of vancomycin |
| 07/15/2004 | US20040136922 film delivers at least one oral care agent, such as antimicrobial agents and salivary stimulants |
| 07/15/2004 | US20040136908 Anti-cd19 immunotoxins |
| 07/15/2004 | DE10312259A1 Kosmetische oder dermopharmazeutische Zusammensetzung, umfassend ein Enzym, das in einem wässrigen Medium unlöslich ist, sowie deren Verwendung Cosmetic or dermopharmaceutical composition comprising an enzyme, which is insoluble in an aqueous medium, and the use thereof |
| 07/15/2004 | DE10260537A1 Peptide mit hohem Cysteingehalt Peptides with high cysteine |
| 07/15/2004 | DE10147991B4 Verfahren zur Diagnose von chronisch entzündlichen Darmerkrankungen A method of diagnosing inflammatory bowel disease |
| 07/15/2004 | CA2774928A1 Binding agents which inhibit myostatin |
| 07/15/2004 | CA2692217A1 Markers for differential diagnosis and methods of use thereof |
| 07/15/2004 | CA2511612A1 Uses of interleukin-18 for treating skin disorders associated with uv radiations |
| 07/15/2004 | CA2511606A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511599A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511522A1 Novel proteins and use thereof |
| 07/15/2004 | CA2511494A1 Non-hypertensive polyethylene glycol-modified hemoglobin as oxygen carrier |
| 07/15/2004 | CA2511492A1 Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections |
| 07/15/2004 | CA2511436A1 Centrosome-associated protein and applications thereof |
| 07/15/2004 | CA2511245A1 Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof |
| 07/15/2004 | CA2511243A1 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 07/15/2004 | CA2511217A1 Ophthalmic formulation for the prevention and treatment of ocular conditions |
| 07/15/2004 | CA2511213A1 Chimeric protein for the screening of agonists and antagonists of cell signalling pathways that are dependent on g-protein-coupled receptors |
| 07/15/2004 | CA2511209A1 Agent for treatment of pemphigoid |
| 07/15/2004 | CA2510311A1 Novel therapeutic targets in cancer |
| 07/15/2004 | CA2510173A1 Vaccine compositions and methods |
| 07/15/2004 | CA2509392A1 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| 07/15/2004 | CA2509241A1 Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases |
| 07/15/2004 | CA2508939A1 Protein arrays |
| 07/15/2004 | CA2508913A1 Angiogenic compounds and uses thereof |
| 07/15/2004 | CA2505842A1 Translational control by small, non-translatable rnas |
| 07/14/2004 | EP1437408A1 Novel antisense oligonucleotide derivatives against hepatitis c virus |
| 07/14/2004 | EP1437366A1 MHC antigen complexes for detecting and purifying antigen-specific T cells |
| 07/14/2004 | EP1437365A1 Use of cardiotrophin in hepatic diseases |
| 07/14/2004 | EP1437363A1 Drug transporter and use thereof |
| 07/14/2004 | EP1437362A1 Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease |
| 07/14/2004 | EP1437141A1 Remedies for bone loss |
| 07/14/2004 | EP1436756A2 Polymorphic marker that can be used to assess the efficacy of interferon therapy |
| 07/14/2004 | EP1436612A2 Neuropilin/vegf c/vegfr 3 materials and methods |
| 07/14/2004 | EP1436430A2 Antisense modulation of fibroblast growth factor receptor 3 expression |
| 07/14/2004 | EP1436429A2 Targeted nucleic acid constructs and uses related thereto |
| 07/14/2004 | EP1436425A2 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease |
| 07/14/2004 | EP1436422A2 Method of determining susceptibility to inflammatory bowel disease |
| 07/14/2004 | EP1436418A2 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 07/14/2004 | EP1436406A2 Method of modulating or examining ku70 levels in cells |
| 07/14/2004 | EP1436397A2 Hepatitis c virus vaccine |
| 07/14/2004 | EP1436396A2 A human g protein coupled receptor |
| 07/14/2004 | EP1436392A2 Gmg-2 polynucleotides and polypeptides and uses thereof |
| 07/14/2004 | EP1436389A2 Thrombin-cleavable chimeric proteins |
| 07/14/2004 | EP1436383A2 Secreted proteins |
| 07/14/2004 | EP1436382A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 07/14/2004 | EP1436330A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2004 | EP1436327A1 Ee3-protein family and corresponding dna sequences |
| 07/14/2004 | EP1436326A2 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
| 07/14/2004 | EP1436322A2 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 07/14/2004 | EP1436321A2 Synthesis of cyclosporin analogs |
| 07/14/2004 | EP1436320A1 T cell epitopes of the cyn d 1 allergen from bermuda grass pollen |
| 07/14/2004 | EP1436319A2 Repetitive motifs from salivary proline rich proteins, mucin and collagen |
| 07/14/2004 | EP1436318A2 Ncam binding compounds |
| 07/14/2004 | EP1436317A1 Molecules that block viral infectivity and methods of use thereof |
| 07/14/2004 | EP1436316A2 Subcellular targeting of therapeutic proteins |
| 07/14/2004 | EP1436314A2 RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIN D1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| 07/14/2004 | EP1436313A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 07/14/2004 | EP1436312A2 Antisense modulation of ksr expression |
| 07/14/2004 | EP1436311A2 Antisense oligonucleotides and methods to induce tumor cell death |
| 07/14/2004 | EP1436310A1 Antisense modulation of vascular endothelial growth factor receptor-2 expression |
| 07/14/2004 | EP1436308A2 Antisense modulation of il-1 receptor-associated kinase-4 expression |
| 07/14/2004 | EP1436307A1 Antisense modulation of nac expression |
| 07/14/2004 | EP1436255A1 Novel compounds and compositions as cathepsin inhibitors |
| 07/14/2004 | EP1436013A2 Method for inducing growth and enhancing survival of nervous tissue |